Peptide therapy TikTok claims: what the science actually supports

What did @wellnesswithelvia actually say?

Elvia says she is stacking "red at" (retatrutide) and "mottie" (MOTS-c), and frames the combination as complementary: retatrutide quiets "food noise" and sets a "metabolic environment," while MOTS-c "supports cellular energy and endurance." She adds that MOTS-c "responds to stimulus" and that resistance training and movement are what tell your body to use energy rather than store it. She closes by saying the stack "doesn't replace habits" but "rewards them."

To her credit, she frames this as personal experience and explicitly says it is not medical advice. She does not claim to cure anything. The framing is aspirational wellness, not clinical. But aspirational framing does not insulate claims from scrutiny, especially when 58,000 people are watching and taking notes.

Does the science back this up?

Retatrutide has real clinical data behind it. MOTS-c in humans is a much thinner story. The combination of the two? There is essentially no human evidence for that stack at all.

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. A phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine) showed up to 24.2% body weight reduction over 48 weeks, which is a genuinely significant number. The "food noise" framing Elvia uses tracks loosely with what participants in GLP-1 trials describe, though that language is patient-reported, not a clinical endpoint.

MOTS-c is a mitochondria-derived peptide. Rodent studies, particularly Kim et al. (2018, Cell Metabolism), showed it improved insulin sensitivity and exercise capacity in aging mice. One small human study by Reynolds et al. (2021, Nature Communications) found circulating MOTS-c levels rise with exercise in humans. That is interesting. It is not evidence that injecting exogenous MOTS-c into a human does the same thing. The leap from "this peptide exists in your body" to "supplementing it works" is not a small leap. It is a canyon.

What did they get wrong (or right)?

She gets credit for the exercise point. The claim that MOTS-c "responds to stimulus" and that training matters is the most defensible thing she says. Reynolds et al. (2021) genuinely supports the idea that MOTS-c is exercise-responsive. Whether exogenous MOTS-c mimics that or stacks on top of it is unknown, but the underlying biology is real.

Where she goes wrong is implying the stack is an established or well-understood intervention. Retatrutide is not FDA-approved as of mid-2025. It is in phase 3 trials. People accessing it are doing so through compounding pharmacies, which operate in a legally and clinically murky space. She does not mention this. She also does not mention that combining a potent triple agonist with any other metabolic compound raises interaction questions that have not been studied. Saying the stack "rewards" good habits is motivating content. It is not pharmacology.

The "food noise" description of retatrutide is also borrowed language from GLP-1 class drugs broadly. Whether retatrutide's glucagon agonism changes that subjective experience compared to semaglutide or tirzepatide is not established in published literature.

What should you actually know?

If you are considering either of these compounds, the information gap between what is posted on TikTok and what is in the clinical literature is significant, and it matters.

Retatrutide is the more studied of the two, but it is still investigational. Accessing it outside a clinical trial means you are using a compounded version with no approved labeling, no established dosing standard, and no long-term safety data. The Jastreboff 2023 trial data is promising but comes from a controlled setting with regular monitoring.

MOTS-c human data is extremely limited. There is no published randomized controlled trial in humans showing that exogenous MOTS-c administration improves energy, endurance, or body composition. Influencer stacks built on rodent data and mechanistic plausibility are a category of wellness content that has a long history of not panning out.

The habit advice, protein, sleep, consistency, training, is sound. That part does not need a peptide stack to be true. If the stack is doing anything in her experience, isolating what it is versus placebo, lifestyle, or the retatrutide alone would require a study design she does not have access to.

• Retatrutide: promising phase 2 data, not approved, compounded access carries real unknowns.
• MOTS-c: interesting basic science, negligible human intervention data.
• The stack combination: no human evidence exists for it.
• Her lifestyle framing is genuinely accurate and worth keeping.